{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:56Z","timestamp":1781585696632,"version":"3.54.5"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This report describes a gastric cancer patient who developed persistent postoperative hyponatremia following surgery, ultimately associated with immune checkpoint inhibitor-induced hypopituitarism with secondary adrenal insufficiency. Initial symptoms, including diarrhea, abdominal pain, and hyponatremia, were misattributed to common postoperative complications. Laboratory testing, including ACTH and cortisol levels, confirmed pituitary insufficiency. Steroid replacement therapy led to rapid symptom improvement and stabilization. This case highlights an underrecognized endocrine complication of immune checkpoint inhibitor therapy, emphasizing the need for early recognition, careful monitoring of endocrine function, and multidisciplinary management in postoperative cancer care.<\/jats:p>","DOI":"10.3389\/fmed.2026.1783352","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:27:24Z","timestamp":1781584044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-induced hypopituitarism presenting as postoperative hyponatremia in a gastric cancer patient: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Yufang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Liaocheng Hospital Affiliated to Shandong First Medical University (Liaocheng People\u2019s Hospital)","place":["Liaocheng, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Liaocheng Hospital Affiliated to Shandong First Medical University (Liaocheng People\u2019s Hospital)","place":["Liaocheng, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid Tumors: a Meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/cancers14041057","article-title":"Immune checkpoint inhibitors as a threat to the hypothalamus-pituitary Axis: a completed puzzle","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/jcm9072033","article-title":"Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review","volume":"29","author":"Okura","year":"2020","journal-title":"J Clin Med."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112687","article-title":"Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment","volume":"29","author":"Chieng","year":"2022","journal-title":"Cancers (Basel)."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3760\/cma.j.cn311282-20200627-00475","article-title":"Expert consensus on immune-related endocrinopathies caused by immune checkpoint inhibitors (2020)","volume":"36","year":"2020","journal-title":"Chin J Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann Transl Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:27:27Z","timestamp":1781584047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":8,"alternative-id":["10.3389\/fmed.2026.1783352"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1783352","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1783352"}}